XML 38 R22.htm IDEA: XBRL DOCUMENT
v3.6.0.2

Shareholders' Equity | 12 Months Ended
--- | ---
Dec. 31, 2016
Equity [Abstract] |
Shareholders' Equity | Shareholders' Equity Issuances of Common Stock In August 2015, the Company closed a public offering of 5,609,756 shares of its common stock, the aggregate proceeds of which were $218,193, net of underwriting discounts of $11,500 and offering expenses paid by the Company of approximately $306, all of which were capitalized. In January 2015, the Company closed a public offering of 4,312,500 shares of its common stock, including 555,556 shares of common stock purchased by affiliates of Third Security. The aggregate proceeds of the offering were $110,041, net of underwriting discounts and commissions of $6,086 and offering expenses paid by the Company of approximately $311, all of which were capitalized. In March 2014 and concurrent with the formation of Intrexon Energy Partners, the Company entered into securities purchase agreements with each of the IEP Investors in Intrexon Energy Partners for the private placement of 972,004 shares of the Company's common stock for gross proceeds of $25,000. Each IEP Investor purchased an amount proportionate to its investment in Intrexon Energy Partners, including 243,001 shares, or $6,250, purchased by an affiliate of Third Security. Dividend to Shareholders In June 2015, the Company distributed to its shareholders 17,830,305 shares of ZIOPHARM common stock, representing all of the equity interests of ZIOPHARM held by the Company at the time of the distribution and resulting in a realized gain of $81,401. The distribution constituted a dividend to shareholders of record as of June 4, 2015. In connection with the distribution, pursuant to the terms of the Company's equity incentive plans, the conversion terms of all outstanding options for shares of the Company's common stock as of June 4, 2015 were adjusted to reflect the value of the distribution with respect to shares of the Company's common stock by decreasing the exercise prices and increasing the number of shares. This adjustment resulted in 312,795 additional shares at a weighted average exercise price of $25.40. Components of Accumulated Other Comprehensive Loss The components of accumulated other comprehensive loss are as follows:
| December 31,
| 2016 |  | 2015
Unrealized loss on investments | $ | (89 | ) |  | $ | (519 | )
Loss on foreign currency translation adjustments | (36,113 | ) |  | (12,233 | )
Total accumulated other comprehensive loss | $ | (36,202 | ) |  | $ | (12,752 | )

X
- References No definition available. + Details
Name: | us-gaap_EquityAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for the entity's redeemable convertible preferred stock as well as the entire disclosure for accounts comprising shareholders' equity, comprised of portions attributable to the parent entity and noncontrolling interests. + References No definition available. + Details
Name: | xon_TemporaryEquityandShareholdersEquityTextBlockTextBlock
Namespace Prefix: | xon_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration